Elsevier MDL announces DiscoveryGate® for Mac OS X “Tiger”

New version brings powerful online research platform to scientific community

Washington D.C., August 29, 2005— Elsevier MDL today announced a new Mac OS X version of its successful DiscoveryGate® content platform. The release is fully Tiger compatible and offers the scientific community broader access to a structure-searchable online platform for integrated researching of scientific content from databases, journal articles, patent publications and reference works.

“As DiscoveryGate’s popularity has steadily grown, one thing we clearly heard from customers was the desire for a Mac-compatible version,” said Elsevier MDL CEO Lars Barfod. “We’re excited to deliver DiscoveryGate for Mac OS X and expand the availability of this fully integrated platform to help researchers rapidly find critical scientific information from a broad array of sources.”

“The unique combination of rock solid UNIX stability and ease-of-use of the Mac interface has driven increasing adoption of Mac OS X in the research, science and engineering fields,” said Ron Okamoto, Apple’s vice president of Worldwide Developer Relations. “We’re thrilled that Elsevier MDL has built upon the success of DiscoveryGate by making its powerful research tool available on the world’s most advanced operating system."

DiscoveryGate incorporates recent upgrades to provide faster responses to complex queries, improved usability and easy installation and maintenance. New data sources recently available through the platform include the xPharm database, the world’s largest pharmacological reference work, and MDL® Patent Chemistry Database, an extensive collection of reaction and substance data for scientists. For more information, visit discoverygate.com or contact an Elsevier MDL Account Manager.

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information visit www.elsevier.com.

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information visit www.reedelsevier.com.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Dr. Phil McHale
Elsevier MDL
VP, Market and Corporate Communications
Phone: (510) 357-2222 ext. 3541
Email: p.mchale@mdl.com


MDL and DiscoveryGate are registered trademarks of MDL Information Systems, Inc. (‘Elsevier MDL’) in the United States. All rights reserved. xPharm is a registered trademark of Elsevier Inc., in the United States and/or other countries. All other trademarks mentioned in this document are the property of their respective owners.